Indonesia raises generics' prices 15%

23 March 2001

Indonesia is increasing generic drug prices 15% from April, in line withthe rise in the cost of pharmaceutical raw materials and fuel prices, and also because of the fall in government subsidy, the head of the country's Food and Drug Control Agency has announced.

In 1999, this subsidy had been 168 billion rupiah ($16.1 million), compared with 105 billion rupiah last year, said Mr Sampurno, adding that the government had not increased the prices of generics, which are 40%-80% cheaper than proprietary drugs, for the last five years. "I call on patients to continue asking doctors to prescribe generic drugs," he said, as these are cheaper while their contents are "basically the same."

The Indonesian Consumers' Foundation has said that it regrets the price rise, reports the Marketletter's local correspondent. Mr Sampurno also said that Indonesia has sufficient drug stocks for this year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight